Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome

Diabetology & Metabolic Syndrome

Henrik Ortsäter²  Alex Rafacho⁴  Åke Sjöholm¹  Petra Wolbert³  Cristiane dos Santos⁴  Liselotte Fransson³ 

[1] Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL, USA;Research Unit, Södertälje Hospital, SE-152 86, Södertälje, Sweden;Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Research Center Floor 3, 118 83, Stockholm, Sweden;Department of Physiological Sciences, Center of Biological Sciences, Federal University of Santa Catarina, Florianópolis, Brazil

关键词: Islet;    Beta-cell;    Insulin;    Metabolic syndrome;    Liraglutide;    Diabetes;    Corticosterone;   

Others  :  812197
DOI  :  10.1186/1758-5996-6-3

 received in 2013-09-27, accepted in 2014-01-09,  发布年份 2014

【 摘 要 】

Background

Glucocorticoid excess is commonly associated with diabetogenic effects, including insulin resistance and glucose intolerance. The effects of the long-term glucagon-like peptide 1 receptor agonist treatment on the metabolic syndrome-like conditions are not yet fully elucidated. Thus, we aimed to test whether long-term liraglutide treatment could be effective as a therapy to counteract the metabolic dysfunctions induced by chronic glucocorticoid exposure.

Methods

Mice were given corticosterone or vehicle via their drinking water for five consecutive weeks. In addition, mice were treated with once-daily injections of either PBS or liraglutide.

Results

Liraglutide treatment slowed progression towards obesity and ectopic fat deposition in liver that otherwise occurred in corticosterone-treated mice. The drug reduced the increment in serum insulin caused by corticosterone, but did not affect the reduction of insulin sensitivity. Furthermore, liraglutide improved glucose control in mice exposed to corticosterone as evident by a delay in the progression towards post-prandial hyperglycemia and enhanced glucose clearance during a glucose tolerance test. Glucose-stimulated C-peptide levels were higher in those mice that had received liraglutide and corticosterone compared to mice that had been treated with corticosterone alone, indicating a positive role of liraglutide for beta-cell function. Morphometric analysis revealed increased beta- and alpha-cell masses that were associated with more Ki67-positive islet cells in corticosterone-treated mice irrespective of whether they were co-treated with liraglutide or not. Liraglutide had no discernible effect on alpha-cell mass.

Conclusion

Liraglutide can be beneficial for subjects at risk of developing metabolic complications as a result of glucocorticoid excess.

【 授权许可】

   
2014 Fransson et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Schacke H, Docke WD, Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002, 96:23-43.
• [2]Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000, 343:230-238.
• [3]Ohneda M, Johnson JH, Inman LR, Unger RH: GLUT-2 function in glucose-unresponsive b cells of dexamethasone-induced diabetes in rats. J Clin Invest 1993, 92:1950-1956.
• [4]Davani B, Portwood N, Bryzgalova G, Reimer MK, Heiden T, Ostenson CG, Okret S, Ahren B, Efendic S, Khan A: Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes. Diabetes 2004, 53(Suppl 1):S51-59.
• [5]Ling ZC, Khan A, Delauny F, Davani B, Ostenson CG, Gustafsson JA, Okret S, Landau BR, Efendic S: Increased glucocorticoid sensitivity in islet beta-cells: effects on glucose 6-phosphatase, glucose cycling and insulin release. Diabetologia 1998, 41:634-639.
• [6]Lambillotte C, Gilon P, Henquin JC: Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997, 99:414-423.
• [7]Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A, Mack AF, Chao CM, Su J, Nitschke R, et al.: Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005, 54:1090-1099.
• [8]Linssen MM, van Raalte DH, Toonen EJ, Alkema W, van der Zon GC, Dokter WH, Diamant M, Guigas B, Ouwens DM: Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells. Cell Signal 2011, 23:1708-1715.
• [9]Weinhaus AJ, Bhagroo NV, Brelje TC, Sorenson RL: Dexamethasone counteracts the effect of prolactin on islet function: implications for islet regulation in late pregnancy. Endocrinology 2000, 141:1384-1393.
• [10]Ranta F, Avram D, Berchtold S, Dufer M, Drews G, Lang F, Ullrich S: Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 2006, 55:1380-1390.
• [11]Fernandez-Mejia C, Medina-Martinez O, Martinez-Perez L, Goodman PA: The human insulin gene contains multiple transcriptional elements that respond to glucocorticoids. Pancreas 1999, 18:336-341.
• [12]Wajngot A, Giacca A, Grill V, Vranic M, Efendic S: The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. Proc Natl Acad Sci U S A 1992, 89:6035-6039.
• [13]Sadry SA, Drucker DJ: Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol 2013, 9:425-433.
• [14]Torekov SS, Madsbad S, Holst JJ: Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev 2011, 12:593-601.
• [15]Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V: Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993, 138:159-166.
• [16]van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M: Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011, 34:412-417.
• [17]Matsuo K, Nambu T, Matsuda Y, Kanai Y, Yonemitsu S, Muro S, Oki S: Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy. Int Med 2013, 52:89-95.
• [18]Shyangdan D, Cummins E, Royle P, Waugh N: Liraglutide for the treatment of type 2 diabetes. Health Technol Assess 2011, 15(Suppl 1):77-86.
• [19]Montanya E: A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opin on Pharmacother 2012, 13:1451-1467.
• [20]Fransson L, Franzen S, Rosengren V, Wolbert P, Sjöholm Å, Ortsäter H: b-cell adaptation in a mouse model of glucocorticoid-induced metabolic syndrome. J Endocrinol 2013, 219:231-241.
• [21]Karatsoreos IN, Bhagat SM, Bowles NP, Weil ZM, Pfaff DW, McEwen BS: Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. Endocrinology 2010, 151:2117-2127.
• [22]Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A: Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc 2013, 8:1149-1154.
• [23]Rafacho A, Ribeiro DL, Boschero AC, Taboga SR, Bosqueiro JR: Increased pancreatic islet mass is accompanied by activation of the insulin receptor substrate-2/serine-threonine kinase pathway and augmented cyclin D2 protein levels in insulin-resistant rats. Int J of Exp Pathol 2008, 89:264-275.
• [24]Rafacho A, Cestari TM, Taboga SR, Boschero AC, Bosqueiro JR: High doses of dexamethasone induce increased b-cell proliferation in pancreatic rat islets. Am J Physiol Endocrinol Metab 2009, 296:E681-689.
• [25]Lee RS, Tamashiro KL, Yang X, Purcell RH, Harvey A, Willour VL, Huo Y, Rongione M, Wand GS, Potash JB: Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Endocrinology 2010, 151:4332-4343.
• [26]Patel R, Patel M, Tsai R, Lin V, Bookout AL, Zhang Y, Magomedova L, Li T, Chan JF, Budd C, et al.: LXRb is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest 2011, 121:431-441.
• [27]Hagberg CE, Mehlem A, Falkevall A, Muhl L, Fam BC, Ortsater H, Scotney P, Nyqvist D, Samen E, Lu L, et al.: Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 2012, 490:426-430.
• [28]Hallberg P, Schwan S, Melhus H: Liraglutide for weight loss in obese people. Lancet 2010, 375:551. author reply 552-553
• [29]Wu L, Olverling A, Fransson L, Ortsäter H, Kappe C, Gao X, Sjöholm Å: Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats. Regul Pept 2012, 177:92-96.
• [30]Perry CM: Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Drugs 2011, 71:2347-2373.
• [31]Larsson H, Ahren B: Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia 1999, 42:936-943.
• [32]Grill V, Pigon J, Hartling SG, Binder C, Efendic S: Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Metabolism 1990, 39:251-258.
• [33]Henriksen JE, Alford F, Ward GM, Beck-Nielsen H: Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997, 40:1439-1448.
• [34]Besse C, Nicod N, Tappy L: Changes in insulin secretion and glucose metabolism induced by dexamethasone in lean and obese females. Obes Res 2005, 13:306-311.
• [35]Gil-Lozano M, Romani-Perez M, Outeirino-Iglesias V, Vigo E, Brubaker PL, Gonzalez-Matias LC, Mallo F: Effects of prolonged exendin-4 administration on hypothalamic-pituitary-adrenal axis activity and water balance. Am J Physiol Endocrinol Metab 2013, 304:E1105-1117.
• [36]Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O, Beck-Nielsen H: Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J of Obes 1983, 7:529-538.
• [37]Verdich C, Toubro S, Buemann B: Lysgard madsen J, juul holst J, astrup a: the role of postprandial releases of insulin and incretin hormones in meal-induced satiety–effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001, 25:1206-1214.
• [38]Kappe C, Patrone C, Holst JJ, Zhang Q, Sjoholm A: Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J of Gastroenterol 2013, 48:322-332.
• [39]Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R, Liraglutide E, Action in Diabetes 5 met SUSG: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
• [40]Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J, Liraglutide Effect Action in Diabetes-6 Study G: Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010, 33:1300-1303.
• [41]Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S, group L-Ss: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
• [42]Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B, Group L-S: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
• [43]Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, Investigators L-S: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 2009, 32:1224-1230.
• [44]Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR, Group L-S: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
• [45]Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, During M, Zdravkovic M, Strauss BJ, Garber AJ, Lead, Groups L-S: Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diab Obes Metab 2009, 11:1163-1172.
• [46]Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, et al.: Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diab 1993, 42:1663-1672.
• [47]Rafacho A, Marroqui L, Taboga SR, Abrantes JL, Silveira LR, Boschero AC, Carneiro EM, Bosqueiro JR, Nadal A, Quesada I: Glucocorticoids in vivo induce both insulin hypersecretion and enhanced glucose sensitivity of stimulus-secretion coupling in isolated rat islets. Endocrinology 2010, 151:85-95.
• [48]Rafacho A, Abrantes JL, Ribeiro DL, Paula FM, Pinto ME, Boschero AC, Bosqueiro JR: Morphofunctional alterations in endocrine pancreas of short- and long-term dexamethasone-treated rats. Horm Metab Res 2011, 43:275-281.
• [49]Filippatos TD, Elisaf MS: Effects of glucagon-like peptide-1 receptor agonists on renal function. World J of Diab 2013, 4:190-201.
• [50]Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC: Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013, 62:2595-2604.